Skip to main content
. 2020 Feb 23;12(2):191. doi: 10.3390/pharmaceutics12020191

Figure 6.

Figure 6

In vivo antitumor efficacies of various MTO formulations in K562/DOX tumor-bearing nude mice. (A) The tumor volume changes during the treatment with various formulations. Data are presented as means ± SD, n = 5. * p < 0.05; ** p < 0.01;*** p < 0.001. (B) The photograph of excised tumors harvested from each group at the end of the experiment. (C) Hematoxylin and eosin (H&E) assays of tumors from K562/DOX tumor xenografts-bearing BALB/c nude mice after being subjected to different treatments for 18 days. Scale bar = 200 μm. (D) TdT-mediated dUTP nick-end labeling (TUNEL) assays of tumors from K562/DOX tumor xenografts-bearing BALB/c nude mice after being given different treatments for 18 days. Scale bar = 200 μm.